唐氏综合征儿童白血病风险的大型队列研究
唐氏综合征患儿急性髓系白血病(AML)5岁前风险显著升高(HR 399),急性淋巴细胞白血病(ALL)风险在各年龄段均升高。
要点
- 唐氏综合征患儿4岁时AML累积发病率1405/10万,14岁时不变。
- 唐氏综合征患儿5岁前AML风险HR为399,巨核细胞白血病HR达1500。
- 唐氏综合征患儿ALL风险5岁前HR 28,5岁及以上HR 21。
核心结论
- 唐氏综合征仍是儿童白血病的重要风险因素,且与AML的关联强度高于既往报道。
研究设计与样本
- 回顾性队列研究,纳入1996-2016年出生于美国7个医疗系统或加拿大安大略省的3 905 399名儿童,随访至癌症诊断、死亡、15岁、退出或2016年12月30日。
- 唐氏综合征通过ICD-9和ICD-10诊断代码识别,癌症诊断通过肿瘤登记链接确定。
- 采用Cox模型估计白血病风险比(HR),调整医疗系统、诊断时年龄、出生年份和性别。
主要发现
- 唐氏综合征患儿中124/4401例诊断白血病,其他儿童中1941/3 900 998例诊断白血病。
- 唐氏综合征患儿AML累积发病率在4岁时为1405/10万(95%CI 1076-1806),14岁时不变。
- 唐氏综合征患儿ALL累积发病率在4岁时为1059/10万(95%CI 755-1451),14岁时为1714/10万(95%CI 1264-2276)。
- 唐氏综合征患儿5岁前AML风险高于其他儿童(HR 399,95%CI 281-566),5岁前巨核细胞白血病HR最高(HR 1500,95%CI 555-4070)。
- 唐氏综合征患儿ALL风险在各年龄段均高于其他儿童(<5岁:HR 28,95%CI 20-40;≥5岁:HR 21,95%CI 12-38)。
临床怎么用
- 对唐氏综合征患儿应关注白血病风险,尤其是5岁前AML和巨核细胞白血病的显著升高。
- 临床监测中需考虑唐氏综合征患儿ALL风险持续存在至5岁以上。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess leukemia risks among children with Down syndrome in a large, contemporary cohort. STUDY DESIGN: Retrospective cohort study including 3 905 399 children born 1996-2016 in 7 US healthcare systems or Ontario, Canada, and followed from birth to cancer diagnosis, death, age 15 years, disenrollment, or December 30, 2016. Down syndrome was identified using International Classification of Diseases, Ninth and Tenth Revisions, diagnosis codes. Cancer diagnoses were identified through linkages to tumor registries. Incidence and hazard ratios (HRs) of leukemia were estimated for children with Down syndrome and other children adjusting for health system, child's age at diagnosis, birth year, and sex. RESULTS: Leukemia was diagnosed in 124 of 4401 children with Down syndrome and 1941 of 3 900 998 other children. In children with Down syndrome, the cumulative incidence of acute myeloid leukemia (AML) was 1405/100 000 (95% CI 1076-1806) at age 4 years and unchanged at age 14 years. The cumulative incidence of acute lymphoid leukemia in children with Down syndrome was 1059/100 000 (95% CI 755-1451) at age 4 and 1714/100 000 (95% CI 1264-2276) at age 14 years. Children with Down syndrome had a greater risk of AML before age 5 years than other children (HR 399, 95% CI 281-566). Largest HRs were for megakaryoblastic leukemia before age 5 years (HR 1500, 95% CI 555-4070). Children with Down syndrome had a greater risk of acute lymphoid leukemia than other children regardless of age (<5 years: HR 28, 95% CI 20-40, ≥5 years HR 21, 95% CI 12-38). CONCLUSIONS: Down syndrome remains a strong risk factor for childhood leukemia, and associations with AML are stronger than previously reported.
引用
- Marlow EC, Ducore J, Kwan ML, et al. Leukemia Risk in a Cohort of 3.9 Million Children with and without Down Syndrome. J Pediatr. 2021. PMID: 33684394. doi:10.1016/j.jpeds.2021.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。